[HTML][HTML] Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease
…, S Khalilnezhad, SE Irac, A Dubuisson, M Chevrier… - Immunity, 2021 - cell.com
Mononuclear phagocytes (MNPs) encompass dendritic cells, monocytes, and macrophages
(MoMac), which exhibit antimicrobial, homeostatic, and immunoregulatory functions. We …
(MoMac), which exhibit antimicrobial, homeostatic, and immunoregulatory functions. We …
[HTML][HTML] A benchmark of batch-effect correction methods for single-cell RNA sequencing data
…, KS Ang, M Chevrier, X Zhang, NYS Lee, M Goh… - Genome biology, 2020 - Springer
Background Large-scale single-cell transcriptomic datasets generated using different
technologies contain batch-specific systematic variations that present a challenge to batch-effect …
technologies contain batch-specific systematic variations that present a challenge to batch-effect …
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
…, V Fernandez, MR Chevrier… - Arthritis Care & …, 2009 - Wiley Online Library
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity.
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity. …
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity. …
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus
…, W Chatham, WJ McCune, M Chevrier… - … : Official Journal of …, 2008 - Wiley Online Library
Objective To determine the association of plasma B lymphocyte stimulator (BLyS) levels,
immunosuppressive therapy, and other clinical parameters with disease activity in systemic …
immunosuppressive therapy, and other clinical parameters with disease activity in systemic …
Novel evidence‐based systemic lupus erythematosus responder index
…, V Strand, A Weinstein, MR Chevrier… - Arthritis Care & …, 2009 - Wiley Online Library
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity.
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity. …
… Chevrier holds a patent for the definition of systemic lupus erythematosus serologic activity. …
Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
…, S Fakharzadeh, S Calabro, M Chevrier… - JAMA …, 2015 - jamanetwork.com
Importance The efficacy of treatment for psoriasis must be balanced against potential adverse
events. Objective To determine the effect of treatment on the risk of serious infections in …
events. Objective To determine the effect of treatment on the risk of serious infections in …
[PDF][PDF] Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells
Human mononuclear phagocytes comprise phenotypically and functionally overlapping
subsets of dendritic cells (DCs) and monocytes, but the extent of their heterogeneity and distinct …
subsets of dendritic cells (DCs) and monocytes, but the extent of their heterogeneity and distinct …
[HTML][HTML] Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection
…, M Chevrier, S Plevy, J Popp, FJ Cornillie, M Lukas… - Gastroenterology, 2016 - Elsevier
Background & Aims Most patients with Crohn’s disease (CD) eventually require an intestinal
resection. However, CD frequently recurs after resection. We performed a randomized trial …
resection. However, CD frequently recurs after resection. We performed a randomized trial …
Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
…, V Ho, K Goyal, S Fakharzadeh, M Chevrier… - Journal of drugs in …, 2015 - europepmc.org
Objective To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab
and other psoriasis treatments in a real-world setting using 2014 Psoriasis Longitudinal …
and other psoriasis treatments in a real-world setting using 2014 Psoriasis Longitudinal …
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …
…, RM Gordon, B Zhou, B Hsu, M Chevrier, M Triebel… - The Lancet, 2018 - thelancet.com
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. …
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. …